Pds Biotechnology Corporation · NASDAQ:PDSB

Pds Biotechnology — Investor Presentation (February 2026)

22 slides from Pds Biotechnology's investor presentation, February 2026

  1. Slide 1: Precision Designed Science for Cancer Patients

    Precision Designed Science for Cancer Patients NASDAQ: PDSB February 2026 1 Confidential © 2025 PDS Biotechnology. All Rights Reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corpo

  3. Slide 3: A Promising Approach to Treating HPV16-Positive Head and Neck Cancers

    A Promising Approach to Treating HPV16-Positive Head and Neck Cancers Targeted immunotherapy with compelling clinical results and regulatory path to accelerated approval CLINICAL INNOVATION INTELLECTUAL PROPERTY PROTECTION VALIDATED PATH FORWARD 39.3 months median overall survival >12 families Phase

  4. Slide 4: Lead Program: Seeking to Deliver the First Targeted Immunotherapy for HPV16-Driven Head and Neck Cancers

    Lead Program: Seeking to Deliver the First Targeted Immunotherapy for HPV16- Driven Head and Neck Cancers – Non-EGFR Driven Cancers  HPV-16 positive cancers are rapidly increasing in the US and EU, due to: 30,000 Annual Number of Oropharyngeal Cancer Cases • Poor uptake of Human Papillomavirus (HPV

  5. Slide 5: HPV16+ Patients Have No Targeted Therapies, Leading to Worse Outcomes

    HPV16+ Patients Have No Targeted Therapies, Leading to Worse Outcomes The gap: No approved therapies specifically target HPV16-positive cancers, a distinct patient population with unique unmet needs PUBLISHED EVIDENCE CURRENT STANDARD OF CARE Two head-to-head studies demonstrate that HPV16-positive

  6. Slide 6: The Versamune Platform for Powerful Anti-Tumor T Cells

    The Versamune® Platform for Powerful Anti-Tumor T Cells A lipid nanoparticle trains the immune system to find and destroy cancer8 WHAT IS VERSAMUNE®? Nanoparticles (~200nm) made from a special lipid (R-DOTAP) that the Nanoparticles sized to 200nm to R-DOTAP forms spherical bilayers immune system rea

  7. Slide 7: PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors

    PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors8 Lymph Node Tumor Dendritic Cell Versamune® + HPV16 E6 & E7 Immune HPVmix (PDS0101) Checkpoint Inhibitor MHC class I CD8+ killer T cell Targeted CD8+ T Cells Tracks to Tumor CD4+ Versamune® MHC class II helper T cell Activated CD8

  8. Slide 8: Pipeline Across Multiple Indications Validated by World-Class Partners

    Pipeline Across Multiple Indications Validated by World-Class Partners Therapy / Treatment Indication P2 P3 Partner PDS0101+ pembrolizumab vs. HPV16-positive recurrent/metastatic head FDA Fast Track pembrolizumab (VERSATILE-003) and neck cancer Versamune® PDS0101+ chemoRT (IMMUNOCERV) Locally advanc

  9. Slide 9: VERSATILE-002: PDS0101 + Pembrolizumab in First-Line HPV16-Positive HNSCC

    VERSATILE-002: PDS0101 + Pembrolizumab in First-Line HPV16-Positive HNSCC Study Key Entry Study Criteria for ICI Endpoints Treatment Design Naïve Subjects PDS0101 HPV16-positive R/M Single-arm study Primary: HNSCC tumors Best overall response (BOR) of confirmed 5 doses: 1 mL 31 sites in US and ≥18 y

  10. Slide 10: PDS0101 + Pembrolizumab: mOS of 39.3 Months

    PDS0101 + Pembrolizumab: mOS of 39.3 Months; 12-18 Months mOS is Benchmark with Pembrolizumab and Pembrolizumab + Chemotherapy9 Durable Survival: 11 Patients Surpassed 30 Months mOS = Median Overall Survival 10 No head-to-head studies have been performed Confidential

  11. Slide 11: PDS0101: Near or Complete Tumor Shrinkage in Hard-to-Treat Patients

    PDS0101: Near or Complete Tumor Shrinkage in Hard-to-Treat Patients (63% had low CPS 1-19)9  Confirmed Disease Control Rate of 77.4%  ORR of 35.8%, Meeting Primary Endpoint  21% of patients had tumor regression of 90- 100% 11 *Investigator assessment Confidential

  12. Slide 12: PDS0101: Well-Tolerated with a Low Incidence of Adverse Events

    PDS0101: Well-Tolerated with a Low Incidence of Adverse Events Treatment related adverse events (TRAEs) Most common Non-Injection n (%) n (%) by Grade in ICI naïve and resistant patients Site Reaction TRAEs Any Combination TRAE 76 (87.4) Fatigue 30 (34.5) Grade 1 40 (46.0) Headache 13 (14.9) Grade 2

  13. Slide 13: VERSATILE-003: Pivotal Phase 3 in Progress

    VERSATILE-003: Pivotal Phase 3 in Progress PDS0101 + pembrolizumab in 1L HPV16-positive R/M HNSCC Final Study Start Interim Analysis 1 Interim Analysis 2 Analysis (mOS) (PFS) (PFS) PDS0101 + Patient Recruitment Survival Follow-up Pembrolizumab Pembrolizumab Patient Recruitment Survival Follow-up Pri

  14. Slide 14: Well-Positioned in 1L HPV16+ R/M HNSCC in the US and Europe

    Well-Positioned in 1L HPV16+ R/M HNSCC in the US and Europe Combinations with pembrolizumab Genmab10 Bicara11 BioNTech12 PDS Biotech 39.3 months Median OS Not disclosed 21.3 months 22.6 months 95% CI (23.9, NE) Population All comers HPV-negative HPV16-positive HPV16-positive Administration IV Q2W un

  15. Slide 15: PDS01ADC: Novel Investigational Tumor Targeting IL-12 Immunocytokine

    PDS01ADC: Novel Investigational Tumor Targeting Interleukin-12 (IL-12) Immunocytokine13 Strong tolerability and potency demonstrated in over 330 patients THE CHALLENGE NHS76 (Tumor Necrosis Targeting Antibody – Binds to IL-12 is a powerful NK* and T cell activator that helps fight cancer, but expose

  16. Slide 16: Upcoming Catalysts

    Upcoming Catalysts VERSATILE- Adoption of Enrollment completion 003 Amended (Head and Protocol - (FDA) PFS data readout neck cancer) (Submission of interim data to FDA) 1Q 2026 2H 2026 1H 2027 2H 2027 PDS01ADC + HAIP PDS01ADC + HAIP Final Data Readout PDS01ADC + Enzalutamide vs Preliminary data Stag

  17. Slide 17: Significant Commercial Opportunity Across Indications

    Significant Commercial Opportunity Across Indications Estimated Market (US Only) >$1.0B >$2.0B >$6.0B ~$2.0B Locally advanced HPV16+ anal, cervical, Biochemically Metastatic HPV16+ HNSCC penile, vaginal, vulvar recurrent prostate colorectal cancer (PDS0101)14 (PDS0101)15-18 cancer and mCRPC (PDS01AD

  18. Slide 18: Global IP Portfolio Secures Key Commercial Markets

    Global IP Portfolio Secures Key Commercial Markets >12 COVERAGE Composition and method claims protecting both platform technology and product candidates USA Europe Mexico Israel China Canada Japan Australia 2042/2043 8 Key Markets | North America, Europe, Asia Pacific, Middle East 18 Confidential

  19. Slide 19: Multiple Opportunities for Value Creation

    Multiple Opportunities for Value Creation Pipeline Optionality Significant IP Estate World-Class Partners >12 patent families •Colon cancer •MD Anderson •Prostate cancer •Mayo Clinic Global coverage: •Others •National Cancer Institute US, Europe, Japan, China, Australia, Canada, Israel, Mexico, Hong

  20. Slide 20: Thank You

    Thank You NASDAQ: PDSB February 2026 20 Confidential © 2025 PDS Biotechnology. All Rights Reserved.

  21. Slide 21: References

    References 1. Harrington, KJ, Burtness B, Greil R, et al. Keytruda With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2022;41:790-802. https://doi.org/10.1200/JCO.21.02508. 2. Damgacioglu H,

  22. Slide 22: References (continued)

    References (continued) 13. Minnar CM et al (2024) Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front. Oncol. 13:1321318.doi: 10.3389/fonc.2023.1321318 14. Triangle Research Group. PDS Proprietary Market Research Report. 2024. 15. Guerendiain D et al; HPV status and HPV

PDS Biotechnology — Investor Presentation (February 2026) on 6ix